Seeking Alpha
21 Nov 2026, 09:01 UTC · 2h ago
Zimmer Biomet: Solid Sales And Cash Flow Drive A Buy
Impact · against what's priced in
Zimmer Biomet reported a 3.1% increase in Q3 net sales, with strength in hips, technology, and robotics offsetting weakness in the knee segment. While the results are positive, the overall growth rate is modest, suggesting limited immediate catalyst potential beyond a valuation play.
- ZBH+0.10
No priced-in read yet
- In context
The company saw a 3.1% jump in Q3 net sales and strong cash flow, though growth was uneven as robust performance in hips and robotics offset shrinking knee sales.
Read from the article alone

Top 2 movers · tap to explore




